✦ LIBER ✦

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

✍ Scribed by William G. Wierda; Thomas J. Kipps; Michael J. Keating; Jennifer R. Brown; John G. Gribben; Mary Browning; Laura Z. Rassenti; Andrew W. Greaves; Donna Neuberg; Susan M. O'Brien;; the CLL Research Consortium

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 264 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25379

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab as treatment for residual di

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt

Alemtuzumab by continuous intravenous in

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Erratum: Alemtuzumab by continuous intra

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views